NEWS - Mar 9, 2020 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development Read more
NEWS - Feb 25, 2020 Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference Read more
NEWS - Jan 10, 2020 Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer Read more
NEWS - Dec 20, 2019 Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool Read more
NEWS - Dec 9, 2019 Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares Read more
NEWS - Dec 3, 2019 Relmada Therapeutics Announces Pricing of Public Offering of Common Stock Read more
NEWS - Oct 15, 2019 Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression Read more
NEWS - Oct 14, 2019 Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15 Read more
